Skip to main content
Erschienen in: Social Psychiatry and Psychiatric Epidemiology 2/2011

01.02.2011 | Original Paper

The association between substance misuse and first-episode psychosis in a defined UK geographical area during the 1990s

verfasst von: Kim Donoghue, Ian Medley, John Brewin, Cristine Glazebrook, Peter Mason, Roch Cantwell, Peter B. Jones, Glynn Harrison, Gillian A. Doody

Erschienen in: Social Psychiatry and Psychiatric Epidemiology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to examine the prevalence of all substance use disorders (SUD) and cannabis-specific SUDs reported in two first-episode epidemiological studies, conducted in the same catchment area, 5 years apart.

Methods

The prevalence of schizophrenia in Nottingham and Aetiology and Ethnicity of Schizophrenia and Other Psychoses studies included all people with a first-episode of psychosis between 1992 and 1994 and 1997 and 1999, respectively. Those individuals with a comorbid diagnosis of a SUD (ICD-10 harmful use or dependence) were identified.

Results

An upward (but not statistically significant) trend in all SUDs was found for the first-episode study population as a whole, between the two cohorts (11.9–18.2%). When analysed by age, a significant increase in cannabis-specific SUDs was observed for all first-episode cases aged 16–29 between cohorts (3.2–10.6%). When analysed by age and gender, a significant increase in all SUDs was apparent for female first-episode patients aged 16–29 between cohorts (6.1–24.2%), this same increase was not seen in male patients.

Conclusions

Illegal drug misuse is common in patients with a first-episode of psychosis. However, most concerning is that when both age and gender are considered, females with a first-episode of psychosis aged 16–29 show a highly significant rise in the prevalence of all SUDs over the 1990s. More recent drug use data from England and Wales shows that the prevalence of drug use in the 21st century is declining; further epidemiological studies are required to determine whether this is also the case in young female first-episode psychosis populations.
Literatur
1.
Zurück zum Zitat Cantor-Graae E, Nordstrom L, McNeil T (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48:69–82CrossRefPubMed Cantor-Graae E, Nordstrom L, McNeil T (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48:69–82CrossRefPubMed
2.
Zurück zum Zitat Owen RR, Fischer EP, Booth BM, Cuffel BJ (1996) Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 47:853–858PubMed Owen RR, Fischer EP, Booth BM, Cuffel BJ (1996) Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 47:853–858PubMed
3.
Zurück zum Zitat Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course or recent-onset schizophrenic disorder. Arch Gen Psychiatry 51:273–279PubMed Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course or recent-onset schizophrenic disorder. Arch Gen Psychiatry 51:273–279PubMed
4.
Zurück zum Zitat Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA 264:2511–2518CrossRefPubMed Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA 264:2511–2518CrossRefPubMed
5.
Zurück zum Zitat McCreadie RG (2002) Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 181:321–325CrossRefPubMed McCreadie RG (2002) Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 181:321–325CrossRefPubMed
6.
Zurück zum Zitat Green B, Young R, Kavanagh D (2005) Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 187:306–313CrossRefPubMed Green B, Young R, Kavanagh D (2005) Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 187:306–313CrossRefPubMed
7.
Zurück zum Zitat Samele C, Patel M, Boydell J, Leese M, Wessely S, Murray R (2007) Physical illness and lifestyle risk factors in people with their first presentation of psychosis. Soc Psychiatry Psychiatr Epidemiol 42:117–124CrossRefPubMed Samele C, Patel M, Boydell J, Leese M, Wessely S, Murray R (2007) Physical illness and lifestyle risk factors in people with their first presentation of psychosis. Soc Psychiatry Psychiatr Epidemiol 42:117–124CrossRefPubMed
8.
Zurück zum Zitat Carrá G, Johnson S (2009) Variation in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK: a systematic review. Soc Psychiatry Psychiatr Epidemiol 44:429–447CrossRefPubMed Carrá G, Johnson S (2009) Variation in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK: a systematic review. Soc Psychiatry Psychiatr Epidemiol 44:429–447CrossRefPubMed
9.
Zurück zum Zitat Larsen TK, Melle I, Auestad B, Friis F, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan TH (2006) Substance abuse in first-episode non-affective psychosis. Schizophr Res 88:55–62CrossRefPubMed Larsen TK, Melle I, Auestad B, Friis F, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan TH (2006) Substance abuse in first-episode non-affective psychosis. Schizophr Res 88:55–62CrossRefPubMed
10.
Zurück zum Zitat Moore TH, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328CrossRefPubMed Moore TH, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328CrossRefPubMed
11.
Zurück zum Zitat Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB (2007) Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction 102:597–606CrossRefPubMed Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB (2007) Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction 102:597–606CrossRefPubMed
12.
Zurück zum Zitat Brewin J, Cantwell R, Dalkin T, Fox R, Medley I, Glazebrook C, Kwiecinski R, Harrison G (1997) Incidence of schizophrenia in Nottingham: a comparison of two cohorts, 1978–80 and 1992–94. Br J Psychiatry 171:140–144CrossRefPubMed Brewin J, Cantwell R, Dalkin T, Fox R, Medley I, Glazebrook C, Kwiecinski R, Harrison G (1997) Incidence of schizophrenia in Nottingham: a comparison of two cohorts, 1978–80 and 1992–94. Br J Psychiatry 171:140–144CrossRefPubMed
13.
Zurück zum Zitat Fearon P, Kirkbride JB, Morgan C, Dazzan P, Morgan K, Lloyd T, Hutchinson G, Tarrant J, Fung WA, Holloway J, Mallett R, Harrison G, Leff J, Jones PB, Murray RM (2006) Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC ÆSOP study. Psychol Med 36:1541–1550CrossRefPubMed Fearon P, Kirkbride JB, Morgan C, Dazzan P, Morgan K, Lloyd T, Hutchinson G, Tarrant J, Fung WA, Holloway J, Mallett R, Harrison G, Leff J, Jones PB, Murray RM (2006) Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC ÆSOP study. Psychol Med 36:1541–1550CrossRefPubMed
14.
Zurück zum Zitat Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A (1992) Schizophrenia: manifestations, incidence, and course in different cultures—a World Health Organisation ten-country study. Psychol Med Monogr Suppl 20:1–97CrossRefPubMed Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A (1992) Schizophrenia: manifestations, incidence, and course in different cultures—a World Health Organisation ten-country study. Psychol Med Monogr Suppl 20:1–97CrossRefPubMed
15.
Zurück zum Zitat World Health Organisation (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. WHO, Geneva World Health Organisation (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. WHO, Geneva
16.
Zurück zum Zitat Cooper JE, Goodhead D, Craig T, Harris M, Howat J, Korer J (1987) The incidence of schizophrenia in Nottingham. Br J Psychiatry 151:619–626CrossRefPubMed Cooper JE, Goodhead D, Craig T, Harris M, Howat J, Korer J (1987) The incidence of schizophrenia in Nottingham. Br J Psychiatry 151:619–626CrossRefPubMed
17.
Zurück zum Zitat World Health Organisation (1994) Schedules for the assessment in neuropsychiatry (SCAN) version 2.0. WHO, Geneva World Health Organisation (1994) Schedules for the assessment in neuropsychiatry (SCAN) version 2.0. WHO, Geneva
18.
Zurück zum Zitat Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:784–788PubMed Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:784–788PubMed
19.
Zurück zum Zitat Bernadt MW, Murray RM (1986) Psychiatric disorder, drinking and alcoholism: what are the links? Br J Psychiatry 148:393–400CrossRefPubMed Bernadt MW, Murray RM (1986) Psychiatric disorder, drinking and alcoholism: what are the links? Br J Psychiatry 148:393–400CrossRefPubMed
20.
Zurück zum Zitat Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, Lloyd T, Holloway J, Hutchinson G, Leff JP, Mallett RM, Harrison GL, Murray RM, Jones PB (2006) Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center ÆSOP study. Arch Gen Psychiatry 63:250–258CrossRefPubMed Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, Lloyd T, Holloway J, Hutchinson G, Leff JP, Mallett RM, Harrison GL, Murray RM, Jones PB (2006) Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center ÆSOP study. Arch Gen Psychiatry 63:250–258CrossRefPubMed
21.
Zurück zum Zitat SPSS for Windows (2005) Rel. 14.0.0 2005. SPSS Inc., Chicago SPSS for Windows (2005) Rel. 14.0.0 2005. SPSS Inc., Chicago
22.
Zurück zum Zitat Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ, Erlbaum Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ, Erlbaum
23.
Zurück zum Zitat Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191CrossRefPubMed Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191CrossRefPubMed
24.
Zurück zum Zitat Koster A, Lajer M, Lindhardt A, Rosenbaum B (2001) Gender differences in first episode psychosis. Soc Psychiatry Psychiatr Epidemiol 43:940–946CrossRef Koster A, Lajer M, Lindhardt A, Rosenbaum B (2001) Gender differences in first episode psychosis. Soc Psychiatry Psychiatr Epidemiol 43:940–946CrossRef
25.
Zurück zum Zitat Hambrecht M, Hafner H (1996) Substance abuse and the onset of schizophrenia. Biol Psychiatry 40:1155–1163CrossRefPubMed Hambrecht M, Hafner H (1996) Substance abuse and the onset of schizophrenia. Biol Psychiatry 40:1155–1163CrossRefPubMed
26.
Zurück zum Zitat Van Mastrigt S, Addington J, Addington D (2004) Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 39:69–72CrossRefPubMed Van Mastrigt S, Addington J, Addington D (2004) Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 39:69–72CrossRefPubMed
27.
Zurück zum Zitat Rabinowitz J, Bromet E, Lavelle J, Carlson G, Kovasznay B, Schwartz J (1998) Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med 28:1411–1419CrossRefPubMed Rabinowitz J, Bromet E, Lavelle J, Carlson G, Kovasznay B, Schwartz J (1998) Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med 28:1411–1419CrossRefPubMed
28.
Zurück zum Zitat Ramsay M, Partridge S (1999) Drug misuse declared in 1998: results from the British crime survey. Home Office Research Study 197. Home Office, London Ramsay M, Partridge S (1999) Drug misuse declared in 1998: results from the British crime survey. Home Office Research Study 197. Home Office, London
29.
Zurück zum Zitat Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD (2006) Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 189:229–234CrossRefPubMed Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD (2006) Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 189:229–234CrossRefPubMed
30.
Zurück zum Zitat Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL (1993) Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis 181:227–232CrossRefPubMed Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL (1993) Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis 181:227–232CrossRefPubMed
31.
Zurück zum Zitat Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002) Self reported cannabis use as a risk factor for schizophrenia in swedish conscripts of 1969: historical cohort study. BMJ 325:1199–1201CrossRefPubMed Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002) Self reported cannabis use as a risk factor for schizophrenia in swedish conscripts of 1969: historical cohort study. BMJ 325:1199–1201CrossRefPubMed
32.
Zurück zum Zitat Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescents and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212–1213CrossRefPubMed Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescents and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212–1213CrossRefPubMed
33.
Zurück zum Zitat Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15–21PubMed Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15–21PubMed
34.
Zurück zum Zitat Bone C, Waldron SJ (1998) New trends in illicit cannabis cultivation in the United Kingdom of Great Britain and Northern Ireland. Bull Narc 50:117–128 Bone C, Waldron SJ (1998) New trends in illicit cannabis cultivation in the United Kingdom of Great Britain and Northern Ireland. Bull Narc 50:117–128
35.
Zurück zum Zitat Potter DJ, Clark P, Brown M (2005) Potency of R9-Thc and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90–94CrossRef Potter DJ, Clark P, Brown M (2005) Potency of R9-Thc and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90–94CrossRef
36.
Zurück zum Zitat Hoare J, Flatley J (2008) Drug misuse declared: findings from the 2007/08 British crime survey. Home Office Statistical Bulletin, 13/08. Home Office, London Hoare J, Flatley J (2008) Drug misuse declared: findings from the 2007/08 British crime survey. Home Office Statistical Bulletin, 13/08. Home Office, London
37.
Zurück zum Zitat Martin G, Wilkinson A, Kapur B (1988) Validation of self-reported cannabis use by urine analysis. Addict Behav 13:147–150CrossRefPubMed Martin G, Wilkinson A, Kapur B (1988) Validation of self-reported cannabis use by urine analysis. Addict Behav 13:147–150CrossRefPubMed
38.
Zurück zum Zitat Kedzior K, Badcock J, Martin-Ivorson M (2006) Validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. Subst Use Misuse 41:743–750CrossRefPubMed Kedzior K, Badcock J, Martin-Ivorson M (2006) Validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. Subst Use Misuse 41:743–750CrossRefPubMed
Metadaten
Titel
The association between substance misuse and first-episode psychosis in a defined UK geographical area during the 1990s
verfasst von
Kim Donoghue
Ian Medley
John Brewin
Cristine Glazebrook
Peter Mason
Roch Cantwell
Peter B. Jones
Glynn Harrison
Gillian A. Doody
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Social Psychiatry and Psychiatric Epidemiology / Ausgabe 2/2011
Print ISSN: 0933-7954
Elektronische ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-009-0175-5

Weitere Artikel der Ausgabe 2/2011

Social Psychiatry and Psychiatric Epidemiology 2/2011 Zur Ausgabe

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.